**Core Concept**
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits platelet aggregation through the blockade of cyclooxygenase (COX) enzymes, specifically COX-1. This blockade prevents the formation of thromboxane A2, a potent platelet activator that plays a crucial role in the development of arterial thrombi.

**Why the Correct Answer is Right**
Aspirin's antiplatelet effect is primarily due to its selective inhibition of COX-1 in platelets, which reduces the production of thromboxane A2. This reduction in thromboxane A2 levels impairs platelet aggregation, thereby decreasing the risk of ischemic events such as myocardial infarction and stroke. The anti-inflammatory properties of aspirin also contribute to its cardiovascular benefits by reducing inflammation in the vascular wall.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while aspirin does have anti-inflammatory properties, its primary mechanism in secondary prevention of ischemic heart disease is through platelet aggregation inhibition.
**Option B:** Incorrect because while beta-blockers do reduce cardiovascular mortality, they do not have a direct effect on platelet aggregation.
**Option C:** Incorrect because statins do lower cholesterol levels, but their primary mechanism in secondary prevention of ischemic heart disease is through lipid lowering and anti-inflammatory effects.

**Clinical Pearl / High-Yield Fact**
Aspirin's antiplatelet effect is dose-dependent, and a daily dose of 75-100 mg is sufficient to achieve optimal cardiovascular protection.

**Correct Answer: A. Aspirin inhibits platelet aggregation through the blockade of COX-1 enzymes, specifically COX-1.**